Baxter International Full Year 2024 Earnings: EPS Misses Expectations

Baxter International (NYSE:BAX) Full Year 2024 Results

Key Financial Results

• Revenue: US$10.6b (up 2.7% from FY 2023).
• Net loss: US$337.0m (down by 294% from US$174.0m profit in FY 2023).
• US$0.66 loss per share (down from US$0.34 profit in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Baxter International EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

The primary driver behind last 12 months revenue was the Medical Products and Therapies segment contributing a total revenue of US$5.21b (49% of total revenue). Notably, cost of sales worth US$6.43b amounted to 60% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$2.82b (62% of total expenses). Explore how BAX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 9.7% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Baxter International (1 is a bit unpleasant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.